

Edgar Filing: CYTODYN INC - Form 8-K

CYTODYN INC
Form 8-K
July 21, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) June 20, 2006

CytoDyn, Inc.

(Exact name of registrant as specified in its charter)

Colorado

000-49908

75-3056237

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

227 E. Palace Avenue, Suite M, Santa Fe, NM 87501

(Address of Principal Executive Offices) (Zip Code)

(505) 988-5520

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to be simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: CYTODYN INC - Form 8-K

- 1.01 Entry into a Definitive Material Agreement
- 2.01 Completion of Acquisition or Disposition of Assets

On July 17, 2006 CytoDyn, Inc. entered into an Acquisition agreement with UTEK Corporation, to acquire 100% of the outstanding stock of Advanced Influenza Technologies, Inc. (AITI), a Florida Corporation in exchange for 2,000,000 unregistered restricted common shares of CytoDyn, Inc stock.

AITI holds the worldwide nonexclusive and exclusive license agreements from the University of Massachusetts for certain technologies as described in patents:

US Patent Application 60/655,979

US 11,362,617 for "Influenza Nucleic Acids Polypeptides and Uses Therof

US 5,643,578

US 6,841,381

European Patents 93907536 and 01202355.2 for "Immunization by Inoculation of DNA Transcription Unit"

The term of the licensing agreement is until the later of 20 years from the filing date of the Licensed Patents or the expiration of the last to expire patent of the Licensed Patents.

Milestone fees are payable to the University per licensed product and due within 30 days of the event of certain occurrences required.

The University shall also receive 4% royalties of net sales of the licensed products.

AITI has \$675,00 in cash as reported on the unaudited financial statements attached. CytoDyn will report in an 8K/A the audited financial statements within the required time period.

AITI also has agreed to fund a two year (\$325,600) unrestricted project for (\$162,800 per year) under a Sponsored Research Agreement with the primary objective during the first year to conduct lab work to provide well documented 3 DNA plasmids (H1,H3 and H5) in preparation for GMP manufacturing. If after one year the desired outcome is not achieved the agreement can be cancelled and the second year's payment is not required.

Item 9.01. Financial Statements and Exhibits

(a) Financial Statements

The unaudited financial statements of AITI have been furnished with this report. CytoDyn will report in an 8K/A the audited financial statements within the required time period.

(d) Exhibits

- 2.01 Agreement and Plan of Acquisition, dated July 17, 2006, by and between Advanced Influenza Technologies, Inc., UTEK Corporation and CytoDyn, Inc.
- 9.01 Exclusive License Agreement, dated July 17, 2006, by and between the University of Massachusetts and Advanced Influenza Technologies, Inc.***
- 9.02 Non-Exclusive License Agreement, dated July 17, 2006, by and between the University of Massachusetts and Advanced Influenza Technologies, Inc.***

Edgar Filing: CYTODYN INC - Form 8-K

9.03 Sponsored Research Agreement, dated July 17, 2006, by and between the University of Massachusetts and Advanced Influenza Technologies, Inc.

99.1 Advanced Influenza Technologies, Inc. Financial Statements for the Interim Period June 9, 2006 to July 18, 2006

*** Confidential treatment has been requested for portions of this exhibit; the omitted material has been separately filed with the Securities Exchange Commission

SIGNATURE

Pursuant to the requirements of Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CytoDyn, Inc.

Date: July 19, 2006

/s/ Allen D. Allen

Allen D. Allen
President